The role of the medical physicist in clinical trials: 2014 insights
The archived Canadian Organization of Medical Physicists meeting in Banff, Alberta, brought together a professional community in 2014. Its scientific programme, abstracts, registration pages and CCPM examination information documented a meeting concerned with practice, evidence and professional development. Exhibitors, sponsors and accommodation details sat alongside business meetings, banquet activities, social events and tourism information.
Within that setting, the role of the medical physicist in clinical trials became a practical question: who ensures that imaging and treatment measurements are consistent, safe and reproducible? The answer reaches beyond equipment calibration. It includes designing protocols, validating dose or image quality, coordinating multicentre work, interpreting deviations and protecting the integrity of endpoints that clinicians will trust.
The 2014 discussions are best read as a snapshot of a changing field. Digital imaging, image-guided treatment and connected trial operations were reshaping how quality was defined. The historical conference programme maps the subjects in view, while the abstracts preserve the professional questions being tested. The focus was whether each measurement could withstand comparison across patients, scanners and institutions.
For Australian teams, these lessons carry added force because trial infrastructure is distributed across metropolitan hospitals, regional services and remote communities. A site may depend on one CT scanner, a small radiotherapy team or interpreter-supported consultation, and a physicist may be shared across several centres. Banff’s Canadian perspective offers a comparison, not a ready-made template.
Imaging protocols as trial infrastructure
Clinical trial imaging is not merely a source of pictures; it is part of the measured intervention. A physicist can specify acquisition parameters, test the scanner or treatment unit, and set acceptance criteria before the first participant is scanned. This may involve CT dose protocols, consistent MRI sequences, PET calibration, ultrasound reproducibility or positioning for radiotherapy.
A durable lesson was to involve medical physicists early, while protocol language was still being negotiated. Procedures should state which scanner features, reconstruction settings, phantoms and dose checks are required, and who may approve a deviation. Leaving these details to local habit can make comparable sites behave differently, weakening safety oversight and imaging endpoints.
Medical physics also connects technology to the clinical question. If a trial depends on tumour size, organ function or response to dose, the measurement must reflect the intended biology rather than local preference. Physicists help distinguish routine care from research-only procedures, identify images requiring central review and check that image processing does not introduce hidden bias.
Quality assurance that protects credibility
Quality assurance in 2014 was shifting from periodic inspection toward protocols designed around risk. Decisive checks can be routine: phantom measurements, patient-specific verification for radiotherapy, cross-calibration of equipment and review of early participant images. These actions can uncover drift before it becomes a pattern of unusable or unsafe data.
The medical physicist is especially valuable when protocols span institutions or use newer techniques. Image-guided radiotherapy, cone-beam CT, four-dimensional imaging and advanced reconstruction create opportunities for variation. A trial-specific procedure can define tolerances for position, dose and image quality, while central review separates a genuine clinical effect from a technical artefact. Standardisation does not remove judgement; it makes judgement visible and accountable.
Quality systems should also specify escalation pathways. A missed test, changed contrast protocol or unavailable scanner can affect eligibility, treatment or endpoint assessment. Australian teams often say they will “circle back” on a problem after discussion, but a trial needs a documented owner, deadline and acceptance rule. Informal goodwill must become a recorded protocol decision.
Geography, access and remote collaboration
The archived feature on rural and remote realities captures why context cannot be separated from measurement. Canadian communities may face long travel distances, limited specialist staffing and dependence on portable equipment. Similar pressures are familiar in northern Australia, where teams around Alice Springs, Katherine and remote clinics balance research value against the burden of travel for participants.
Remote participation does not justify a lower standard of quality; it requires a different operating model. Core protocols, phantom schedules and data definitions can remain consistent, while local procedures account for connectivity, scanner maintenance, time zones and staff turnover. Teleconference support can troubleshoot problems, and central physics review can assess images without requiring every participant to travel to a metropolitan centre.
In Aboriginal and Torres Strait Islander health research, engagement must also be led locally. Community-controlled governance, cultural safety, appropriate interpretation and transparent feedback are part of trial governance, not optional additions. A physicist advising on dosimetry or image acquisition must understand who authorises the work, how participants are supported, and whether the procedure offers a fair return on their time and trust.
Capabilities for Australian trial teams
Australian networks can translate these lessons into a compact set of operational capabilities. The aim is a clear line from a scientific endpoint to a verifiable measurement, one that survives staff turnover, equipment replacement and the distance between coordinating and participating sites.
These prompts are useful during preparation and site activation, since gaps in imaging quality or dose assurance are often discovered after recruitment has begun.
Capabilities worth strengthening
- Assign a named medical physicist to protocol development, site readiness and quality assurance, with protected time for regional centres.
- Record acquisition, reconstruction, phantom and dosimetry requirements in the protocol, including tolerances for closing deviations.
- Maintain central image and dose review that supports sites without removing local clinical decisions or community oversight.
- Budget for phantom scans, calibration, data transfer, travel and remote support rather than treating them as incidental costs.
- Keep amendments, scanner changes and corrective actions in a searchable record that demonstrates how data quality was protected.
Questions to settle before activation
- Which imaging or treatment measurements are primary endpoints, secondary endpoints or routine safety checks?
- What must be verified before activation, after installation, after maintenance and when equipment performance changes?
- Who can approve a protocol deviation, and what evidence must accompany that approval?
- Can remote sites meet the same review schedule, data format and escalation pathway as metropolitan sites?
- How will participants and local communities be told when research procedures differ from routine care?
Regulation, funding and Australian trial practice
Australian trial delivery operates through public hospitals, universities, private providers and dedicated clinical trials units. Major centres in Melbourne, Sydney and Brisbane often have established research infrastructure, while regional hospitals may participate with fewer dedicated staff. The physicist’s role can range from hands-on work to remote consultation, so agreements must define who performs each check and how evidence reaches the coordinating team.
Funding shapes this work. Projects may draw on NHMRC grants, university programs, state health services, industry sponsorship or collaborative networks, each with different validation and documentation expectations. State and territory ethics and health requirements also differ. A site cannot assume another jurisdiction’s approval covers every local procedure or information system.
The expectation of a “fair go” adds a dimension of access. Remote and Indigenous participants should not enter research only through routes convenient for metropolitan teams. Local partnerships, interpreter support, reasonable travel reimbursement and accessible consent help maintain trust. In a professional culture where “no worries” may mean “we’ll sort it out”, participants still need plain explanations of risks, responsibilities and what happens if their trial is discontinued.
From conference insight to coordinated action
The value of the Banff meeting was not a single technique but a broader view of the profession: medical physicists protect participants, make measurements defensible and keep distributed teams aligned. That view remains relevant as trials adopt new modalities and more complex data pathways. The archived scientific programme provides context for comparing past practice with current expectations, while the site’s conference contact details provide a reference for professional and historical enquiries.
Act on that lesson at the next trial-planning meeting: invite the medical physicist before imaging and treatment procedures are locked, assign ownership of the quality checks, and place participant safety and central review beside recruitment milestones. Make the first site-readiness decision explicit, document who can approve exceptions, and give regional partners a genuine role in the plan. Trial quality is built through these decisions, and the profession’s greatest contribution is ensuring that the evidence protects the people who provide it.